Author: Benzinga Newsdesk | August 11, 2025 06:03am
Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.12) by 13.82 percent. This is a 40 percent decrease over losses of $(0.10) per share from the same period last year.